The global peptide therapeutics market size was valued at USD 45.43 billion in 2023. It is projected to reach from USD 48.11 ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Blood tests can also help diagnose systolic heart failure, such as the blood test for B-type natriuretic peptide (BNP), a ...

Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Serum uric acid (SUA), a product of ...

This growth can be attributed to various factors, including the increasing incidence of chronic diseases, a deeper understanding of molecular biology, and the expanding applications of peptide ...

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic ...

In patients with chronic coronary heart disease associations between the plasma concentrations of 6 biomarkers and the risk of cardiovascular death were sustained for at least 15 years after the ...

In patients with chronic coronary heart disease, biomarkers that reflect different pathophysiological pathways are associated with the risk of cardiovascular death for at least the next 15 years.

Thus, the clinical and hemodynamic benefits and safety of nesiritide are preserved in decompensated congestive heart failure patients receiving chronic β blockade.

NICE's guideline on diagnosis and management of chronic heart failure in adults recommends that reviews are offered every 6 months for people whose condition is stable, but clinical experts ...